Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.43, $0.32 better than the analyst estimate of $0.11. Revenue for the quarter came in at $59.1 million versus the consensus estimate of $55.45 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.